Novo Nordisk A/S - share repurchase programme
10 Junio 2024 - 7:15AM
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 10 June 2024 – On 6 May
2024, Novo Nordisk initiated a share repurchase programme in
accordance with Article 5 of Regulation No 596/2014 of the European
Parliament and Council of 16 April 2014 (MAR) and the Commission
Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe
Harbour Rules"). This programme is part of the overall share
repurchase programme of up to DKK 20 billion to be executed during
a 12-month period beginning 6 February 2024.
Under the programme initiated 6 May 2024, Novo Nordisk will
repurchase B shares for an amount up to DKK 2.2 billion in the
period from 7 May 2024 to 5 August 2024.
Since the announcement 3 June 2024, the following transactions
have been made:
|
Number ofB shares |
Averagepurchase price |
Transactionvalue, DKK |
Accumulated, last announcement |
632,545 |
|
577,914,385 |
3 June
2024 |
38,500 |
921.24 |
35,467,783 |
4 June
2024 |
39,000 |
932.56 |
36,369,979 |
6 June
2024 |
38,500 |
968.61 |
37,291,383 |
7 June
2024 |
38,000 |
978.72 |
37,191,306 |
Accumulated under the programme |
786,545 |
|
724,234,837 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
10,886,359 B shares of DKK 0.10 as treasury shares, corresponding
to 0.2% of the share capital. The total amount of A and B shares in
the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 20 billion during a 12-month period beginning 6 February 2024.
As of 7 June 2024, Novo Nordisk has since 6 February 2024
repurchased a total of 9,520,795 B shares at an average share price
of DKK 866.73 per B share equal to a transaction value of DKK
8,251,969,609.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 66,000 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and
YouTube.
Contact for further information.
Media: |
|
Ambre
James-Brown +45 3079 9289 abmo@novonordisk.com |
Liz
Skrbkova (US) +1 609 917 0632
lzsk@novonordisk.com |
Investors: |
|
Jacob
Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com
|
David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com
|
Mark
Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com
|
Sina
Meyer +45 3079 6656azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259fptr@novonordisk.com |
Ida
Melvold Gjøsund+45 3077 5649 idmg@novonordisk.com |
Company announcement No 46/2024
- CA20240610 Safe Harbour
- 20240610 safe harbour transaction details
Novo Nordisk (TG:NOV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Novo Nordisk (TG:NOV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024